Publication: Nivolumab induced discolouration of the tongue: a case report
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Yildirim, Dilek
Date
Language
Type
Embargo Status
No
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Currently, immune checkpoint inhibitors are used in the treatment of ovarian cancer. Immunotherapy agents occasionally cause the development of skin reactions characterized by mild erythematous and maculopapular rashes, usually involving the trunk and extremities of the body, which may occasionally present with pruritus. It is especially seen in the use of anti-PD-1 (nivolumab and pembrolizumab) treatment agents. In this case report, we present a patient who developed discoloration of the tongue toxicity after nivolumab treatment in ovarian cancer patients. Discoloration of the tongue, which is one of the rare side effects of immunotherapy, and factors that may be associated with it are discussed in this case.
Source
Publisher
Taylor and Francis
Subject
Citation
item.page.haspartof
Source
Immunotherapy
item.page.ispartofseries
item.page.edition
DOI
10.1080/1750743X.2025.2533105
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A
